The Technical Analyst
ALX Oncology Holdings [ALXO]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
ALX Oncology Holdings Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
4.65% $16.22
America/New_York / 24 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 813.47 mill |
| EPS: | -3.74 |
| P/E: | -4.34 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 50.15 mill |
| Avg Daily Volume: | 0.469 mill |
| RATING 2024-04-24 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -4.34 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.74x |
| Company: PE -4.34 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.121 (-99.25%) $-16.10 |
| Date: 2024-04-25 |
| Expected Trading Range (DAY) |
|---|
|
$ 15.33 - 17.11 ( +/- 5.46%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-16 | Pons Jaume | Buy | 25 846 | Common Stock |
| 2024-04-16 | Pons Jaume | Sell | 50 000 | Common Stock |
| 2024-04-16 | Pons Jaume | Sell | 25 846 | Employee Stock Option (right to buy) |
| 2024-04-04 | Pons Jaume | Sell | 20 000 | Common Stock |
| 2024-03-14 | Lettmann Jason | Buy | 4 400 | Common Stock |
| INSIDER POWER |
|---|
| 87.36 |
| Last 97 transactions |
| Buy: 3 594 697 | Sell: 591 760 |
Forecast:
16:00 - $16.21
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $16.21
Forecast 2: 16:00 - $16.21
Forecast 3: 16:00 - $16.21
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $16.22 (4.65% ) |
| Volume | 0.437 mill |
| Avg. Vol. | 0.469 mill |
| % of Avg. Vol | 93.07 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ALXO
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $13.99 | N/A | Active |
|---|
ALXO
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was founded in 2015 and is headquartered in South San Francisco, California.
Last 10 Buy Signals
Latest Press Releases
2024-04-24 10:00:00 - Press Release
Alx Oncology Announces Two Evorpacept Abstracts Accepted For Poster Presentation At 2024 Asco Annual Meeting
South san francisco, calif., april 24, 2024 (globe newswire) -- alx oncology holdings inc., (“alx oncology” or “the company”) (nasdaq: alxo), an immuno-oncology company developing therapies that block the cd47 immune checkpoint pathway, today announced the acceptance of two abstracts for poster presentation at the american society of cancer oncology (“asco”), which will be held in chicago from may 31-june 4, 2024.
2024-04-09 17:30:00 - Press Release
Alx Oncology Reports Encouraging Clinical Data Of Evorpacept In Combination With Standard-of-care In An Ongoing Phase 1/2 Clinical Trial In Patients With Relapsed Or Refractory B-cell Non-hodgkin Lymphoma (“r/r B-nhl”)
– twenty patients with indolent (n=18) and aggressive (n=2) r/r b-nhl received evorpacept plus standard rituximab and lenalidomide (“r2”)– evorpacept plus r2 was well tolerated with a safety profile similar to historical r2 – the combination achieved promising initial activity with a best overall response rate (“orr”) of 94% and a complete response rate (“crr”) of 83% in patients with indolent r/r b-nhl (r2 historical crr benchmark is 34%)
2024-03-07 16:03:00 - Press Release
Alx Oncology Reports Fourth Quarter And Full Year 2023 Financial Results And Provides Corporate Update
South san francisco, calif., march 07, 2024 (globe newswire) -- alx oncology holdings inc., (“alx oncology” or “the company”) (nasdaq: alxo), an immuno-oncology company developing therapies that block the cd47 immune checkpoint pathway, today reported financial results for the fourth quarter and full year ended december 31, 2023, and provided a corporate update.
2024-03-05 16:30:00 - Press Release
Alx Oncology Announces Two Evorpacept Clinical Abstracts Accepted For Presentation At The Aacr Annual Meeting
- investigator-initiated trial in patients with relapsed or refractory b-cell non-hodgkin lymphoma selected for oral presentation
2023-11-13 16:05:00 - Press Release
Alx Oncology Reports Third Quarter 2023 Financial Results And Provides Corporate Update
South san francisco, calif., nov. 13, 2023 (globe newswire) -- alx oncology holdings inc., (“alx oncology” or “the company”) (nasdaq: alxo), an immuno-oncology company developing therapies that block the cd47 immune checkpoint pathway, today reported financial results for the third quarter ended september 30, 2023, and provided a corporate update.
Latest News
2024-04-11 10:31:18 - Zacks Investment Research
ALX Oncology (ALXO) Posts Upbeat Results From Lymphoma Study
ALX Oncology (ALXO) announces positive results from an early to mid-stage study of an investigational combination regimen to treat indolent and aggressive R/R B-NHL.
2023-12-22 16:21:22 - InvestorPlace
7 Small-Cap Stocks That Wall Street Loves for Good Reason
As we head into 2024, it's common for investors to look back on 2023. Much of this year had investors in a defensive posture.
2023-12-08 08:30:00 - Market Watch
ALX Oncology shares jump 9% after Jefferies upgrade
ALX Oncology Holdings Inc. shares ALXO, +9.73% climbed 9% premarket on Friday after Jefferies analysts upgraded the stock to buy, from hold. The stock is “very cheap,” the analysts wrote, given that the company is set to have results from three promising phase 2 trials in 2024.
2023-10-09 00:38:06 - Seeking Alpha
ALX Oncology: On Right Track With Latest Interim Analysis Of Evorpacept
ALX Oncology reported positive interim results from its phase 2 study using its anti-CD47 drug for HER2-positive gastric/gastroesophageal junction cancer. Final results from the ASPEN-06 study are expected to be released in Q2 2024, potentially leading to further gains for investors. ALXO also announced a cash raise of $55 million, reducing the need for a future cash raise and lowering the risk of dilution.
2023-10-04 12:46:31 - Zacks Investment Research
ALX Oncology (ALXO) Up 56% on Upbeat Gastric Cancer Study Data
Interim data from a mid-stage study shows that a combination regimen of ALX Oncology's (ALXO) lead candidate achieved 52% ORR in certain gastric cancer patients.
2023-10-03 08:47:59 - Proactive Investors
ALX Oncology stock doubles on early data from phase II cancer trial
ALX Oncology Holdings Inc saw its stock value double in pre-market trading on the heels of promising interim data from a phase II study assessing the potential of its lead asset in cancer of the stomach and esophagus. The ASPEN-06 clinical evaluated the effectiveness of evorpacept in treating patients with HER2-positive gastric and gastroesophageal junction (GEJ) cancer.
2023-10-02 16:05:00 - GlobeNewsWire
ALX Oncology to Host Investor Call and Webcast on October 3, 2023 to Share Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer
SOUTH SAN FRANCISCO, Calif., Oct. 02, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced the hosting of an investor call and webcast on Tuesday, October 3rd at 8:00 AM EDT to share interim Phase 2 ASPEN-06 clinical trial results of evorpacept for the treatment of advanced HER2-positive gastric cancer.
2023-08-31 07:00:00 - GlobeNewsWire
ALX Oncology Announces September Investor Conference Participation
SOUTH SAN FRANCISCO, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that management will participate in two upcoming investor conferences.
2023-08-10 11:31:10 - Zacks Investment Research
ALX Oncology Holdings Inc. (ALXO) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
ALX Oncology Holdings Inc. (ALXO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
2023-01-03 07:00:00 - GlobeNewsWire
ALX Oncology to Present at the 41st Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint pathway, today announced that Jaume Pons, Ph.D., Founder, President and Chief Executive Officer, will present a company overview at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10 at 10:30 am PT at the Westin St. Francis in San Francisco.